Epirus Biopharmaceuticals, Inc. filed a notice of intent of asset sale in the US Bankruptcy Court for the sale of certain assets on December 11, 2017. The debtor seeks to sell its certain assets to Cavion, Inc. for a purchase price of $0.5 million in cash pursuant to an asset purchase agreement dated December 6, 2017. The debtor’s assets include molecular compound known as Z944. Under the terms of the agreement, the buyer shall make an initial deposit if $0.05 million. The buyer is represented by Christian Plaza of Cooley LLP as its legal counsel.